Last reviewed · How we verify
Test Group (B):
Testosterone replacement therapy to treat hypogonadism.
Testosterone replacement therapy to treat hypogonadism. Used for Hypogonadism in males.
At a glance
| Generic name | Test Group (B): |
|---|---|
| Also known as | Natural progesterone 25 mg Subcutaneously (Prolutex) daily from day 5 to trigger |
| Sponsor | Trust Fertility Clinic |
| Drug class | androgen |
| Target | androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Testosterone replacement therapy involves administering exogenous testosterone to replace the body's natural production, which is deficient in individuals with hypogonadism. This can help alleviate symptoms such as low libido, fatigue, and decreased muscle mass. The goal is to restore normal testosterone levels and improve overall quality of life.
Approved indications
- Hypogonadism in males
Common side effects
- Acne
- Hair loss
- Sleep apnea
- Edema
- Increased red blood cell count
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test Group (B): CI brief — competitive landscape report
- Test Group (B): updates RSS · CI watch RSS
- Trust Fertility Clinic portfolio CI